LuckCong's Health Blog

Clinical encounter cirrhosis, liver cancer, hepatitis B virus is the cause of its long - In the body copy, long-term chronic liver inflammation, fibrosis accumulation. A large number of pathological data confirm that The vast majority (80% to 100%) of hepatitis B virus carriers have varying degrees of liver inflammation Disease and changes in fibrosis. To that end, carriers of hepatitis B should be anti-viral treatment, with a view to curb Viral replication, the suspension of the liver inflammation and fibrosis and ultimately reduce the occurrence of liver cirrhosis and liver cancer Rate. The treatment of choice target Hepatitis B virus carriers of the anti-viral treatment should have a choice, if the target should be: (1) of the liver biopsy showed inflammation activities. And should therefore be HBV to mobilize as much as possible For people living with liver biopsy, in order to clear the extent of liver inflammation. (2) of the hepatitis B virus replication of high - State. Non-persons cases should be more than two follow-up, if necessary, be reviewed. Anti-retroviral therapy difficult The current antiviral drugs, including lamivudine, ALT normal Interferon for hepatitis B virus carrying Those with less effective anti-viral. Response (1) to explore new and effective anti-viral drugs, It is reported that entecavir of anti-viral effect ALT from the baseline effects for the treatment of hepatitis B virus carriers to provide new hope. (2) A joint anti-viral drugs or sequential therapy, internal hospitals tried a variety of programs, but what The best programs, the need to explore. In short, the hepatitis B virus carriers should adopt a positive attitude toward treatment, the treatment of difficulties ranging from Not in treatment, treatment should not wait for its natural ALT increased after anti-virus Treatment is a negative approach is not conducive to the hepatitis B control.